Ubidecarenone

In the clinical treatment of cardiovascular diseases and metabolic diseases, regulation of mitochondrial energy metabolism is an important intervention direction. Ubidecarenone, as an endogenous quinone compound, falls into the category of coenzyme drugs. It participates in the process of the mitochondrial electron transport chain to improve the production efficiency of adenosine triphosphate, and simultaneously has the effects of scavenging oxygen free radicals and stabilizing cell membrane structure. Clinically, it is mainly used for the adjuvant treatment of cardiovascular diseases such as congestive heart failure, coronary heart disease and viral myocarditis. It can also be used to improve liver function injury caused by radiotherapy and chemotherapy, as well as for nutritional intervention in people with fatigue and low immunity related to coenzyme Q10 deficiency. Elderly patients with chronic diseases and people engaging in high-intensity exercise are also its main applicable groups.

The global ubidecarenone market size was approximately USD 1.27 billion in 2023, with a compound annual growth rate maintained at around 7.2%. The demand growth mainly comes from the increasing prevalence of cardiovascular diseases and the expansion of applications in the nutrition and health care field. China is the world's largest producer of ubidecarenone API, with production capacity accounting for more than 85% of the global total. Leading manufacturers are concentrated in Zhejiang, Shandong and other regions. On the preparation side, more than 30 domestic generic drugs have been approved so far. Since 2021, it has been included in the provincial centralized procurement catalogs of multiple provinces, with the average price reduction of selected products exceeding 60%, and the accessibility for patients has been significantly improved.

The original research enterprise of ubidecarenone is Eisai Co., Ltd. of Japan, with the original brand name Neuquinon. The core compound patent expired globally in 1985. At present, the main dosage forms of the original research product approved are tablets and soft capsules, with common specifications including 10mg and 20mg. It has been included in the *Catalogue of Chemical Reference Preparations (9th Batch)* of China, and is also listed in the FDA Reference Preparation Catalogue. According to the domestic API registration platform, there are 24 A-status registration numbers for ubidecarenone API at present, covering domestic and imported manufacturers. More than 50 ubidecarenone oral preparations have been approved for marketing in China, covering multiple dosage forms such as tablets, soft capsules and capsules. (Data as of May 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for ubidecarenone API. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day, which can meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and provide reliable reference material support for the whole-process R&D links of API and preparation enterprises, including quality research, stability study, registration and declaration, etc.